DaVita Inc.
Financial Performance
DaVita Revenue & Financials
Revenue
$13.6B (FY2025)
Market Cap
$12.4B
Net Income
$746.8M
Employees
78,000
What is DaVita's revenue?
DaVita had $13.6B in revenue for fiscal year 2025, up 6.5% from 2024. Net income was $746.8M.
- Latest revenue
- $13.6B (FY2025)
- Year-over-year
- +6.5%
- Growth rate (CAGR)
- 2.7% over 9 years
- Peak revenue
- $13.6B (FY2025)
- Years of data
- 10
- Employees
- 78,000
- What is DaVita's operating income?
- DaVita reported operating income of $2B for fiscal year 2025. sec.gov
- How much profit does DaVita make?
- DaVita reported net income of $746.8M for fiscal year 2025. investors.davita.com
- How many employees does DaVita have?
- DaVita has about 78,000 employees.
Financial Analysis
DaVita reported 2025 revenue of $13.643 billion (up 6.5% from $12.816 billion in 2024), operating income of $2.044 billion, and net income attributable to DaVita of $747 million. Adjusted diluted EPS from continuing operations was $10.78. Operating cash flow was $1.887 billion and free cash flow $1.024 billion, and the company repurchased 12.7 million shares at an average $140.09. In Q2 2026 revenue reached $3.554 billion, operating income $579 million (16.3% margin), and diluted EPS $4.02. DaVita guides to 2026 adjusted EPS of $14.10 to $15.20 and free cash flow of $1.0 to $1.25 billion. It pays no dividend and returns cash through buybacks. DaVita Inc. is a massive healthcare provider focused on kidney care, maintaining a market valuation generally over $10 billion.
Revenue Trend Analysis
YoY Change
+6.5%
9-Year CAGR
+2.7%
Peak Year
2025
Trend
Consistent Growth
DaVita Inc. has 10 full fiscal year figures on this page, compounding at +2.7% annually over 9 years. The most recent year saw a 6.5% increase versus the prior year. Annual revenue peaked in fiscal year 2025 at $13.6B. Of 9 comparable year-over-year steps, 7 showed growth and 2 showed a decline.
Annual revenue history
| Fiscal Year | Revenue | Operating Income | Net Income | YoY Change | Source |
|---|---|---|---|---|---|
| FY2025 | $13.6B | $2Bfiling | $746.8M | +6.5% | investors.davita.com 2025 revenue was $13.643B; operating income $2.044B; net income attributable to DaVita $746.8M; adjusted diluted EPS from continuing operations $10.78. |
| FY2024 | $12.8B | $2.1Bfiling | $936.3M | +5.6% | data.sec.gov 2024 revenue was $12.81555B and net income was $936.342M. |
| FY2023 | $12.1B | $1.6Bfiling | $691.5M | +4.6% | data.sec.gov 2023 revenue was $12.140147B as dialysis volumes and reimbursement drove growth. |
| FY2022 | $11.6B | $1.3Bfiling | $560.4M | -0.1% | data.sec.gov 2022 revenue was $11.609894B. |
| FY2021 | $11.6B | $1.8B | $978.5M | +0.6% | DaVita Inc. annual report (Form 10-K, SEC EDGAR, filed 2024-02-14) Fiscal year ended 2021-12-31. |
| FY2020 | $11.6B | $1.7B | $773.6M | +1.4% | DaVita Inc. annual report (Form 10-K, SEC EDGAR, filed 2023-02-22) Fiscal year ended 2020-12-31. |
| FY2019 | $11.4B | $1.6B | $811M | -0.1% | DaVita Inc. annual report (Form 10-K, SEC EDGAR, filed 2022-02-11) Fiscal year ended 2019-12-31. |
| FY2018 | $11.4B | $1.5B | $159.4M | +4.9% | DaVita Inc. annual report (Form 10-K, SEC EDGAR, filed 2021-02-12) Fiscal year ended 2018-12-31. |
| FY2017 | $10.9B | $1.8B | $663.6M | +1.6% | DaVita Inc. annual report (Form 10-K, SEC EDGAR, filed 2020-02-21) Fiscal year ended 2017-12-31. |
| FY2016 | $10.7B | $2B | $879.9M | — | DaVita Inc. annual report (Form 10-K, SEC EDGAR, filed 2019-02-22) Fiscal year ended 2016-12-31. |
Click any row to see year details.
DaVita Inc. balance sheet and cash flow
Balance-sheet figures are as of each fiscal year end; cash-flow figures cover the fiscal year. Taken from the company's annual report on Form 10-K, linked on each row. Free cash flow here is operating cash flow less capital expenditures, calculated by CorpDigest. In some years total assets exceed liabilities plus shareholders' equity because the company reported redeemable preferred stock or non-controlling interests outside both.
| Fiscal Year | Operating cash flow | Capital expenditures | Total assets | Total liabilities | Shareholders' equity | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $1.9B | $575.9M | $17.5B | $16.3B | -$651.1M | $1.3B | Form 10-K |
| FY2024ended Dec 31, 2024 | $2B | $555.4M | $17.3B | $15.2B | $121.1M | $1.5B | Form 10-K |
| FY2023ended Dec 31, 2023 | $2.1B | $568M | $16.9B | $14.2B | $1.1B | $1.5B | Form 10-K |
| FY2022ended Dec 31, 2022 | $1.6B | $603.4M | $16.9B | $14.7B | $712.3M | $961.1M | Form 10-K |
| FY2021ended Dec 31, 2021 | $1.9B | $641.5M | $17.1B | $14.8B | $755.5M | $1.3B | Form 10-K |
| FY2020ended Dec 31, 2020 | $2B | $674.5M | $17B | $14.1B | $1.4B | $1.3B | Form 10-K |
| FY2019ended Dec 31, 2019 | $2.1B | $766.5M | $17.3B | $13.8B | $2.1B | $1.3B | Form 10-K |
| FY2018ended Dec 31, 2018 | $1.8B | $987.1M | $19.1B | $14.1B | $3.7B | $784.5M | Form 10-K |
| FY2017ended Dec 31, 2017 | $1.9B | $905.3M | $19B | $13.1B | $4.7B | $1B | Form 10-K |
| FY2016ended Dec 31, 2016 | $2B | $829.1M | $18.8B | $12.9B | $4.6B | $1.1B | Form 10-K |
Keep researching DaVita
DaVita Revenue and Financial FAQ
What are DaVita Inc.'s annual consolidated revenues and operating income?
DaVita reported $13.643 billion in 2025 revenue, up from $12.816 billion in 2024. Operating income was $2.044 billion. In Q2 2026 revenue was $3.554 billion and operating income $579 million.
How much annual operating cash flow and free cash flow does DaVita generate?
DaVita generated $1.887 billion in operating cash flow and $1.024 billion in free cash flow in 2025. For 2026 it guides to $1.0 billion to $1.25 billion of free cash flow.
What is DaVita's capital return strategy regarding share repurchases?
DaVita pays no regular dividend and returns cash through buybacks. It repurchased 12.7 million shares in 2025 at an average $140.09, and another 2.2 million in Q2 2026 at about $154.95. Its share count has fallen by more than half over the past decade.
How large is DaVita's corporate debt load and leverage ratio?
DaVita uses significant debt to fund buybacks and targets leverage of roughly 3.0x to 3.5x adjusted EBITDA. In Q2 2026 it added a $500 million Term Loan B-2 tranche.
How does patient treatment volume and mortality impact DaVita's financial performance?
DaVita delivered about 92,600 U.S. treatments per day in Q2 2026. Normalized non-acquired treatment growth was only 0.3% year over year, so patient mortality, new patient starts, and missed treatments matter a lot to results.
What was the financial impact of the sale of DaVita Medical Group to Optum in 2019?
DaVita sold DaVita Medical Group to UnitedHealth's Optum in June 2019 for about $4.34 billion and used the proceeds mainly for share repurchases and debt reduction.
What is DaVita's 2026 guidance?
After Q2 2026, DaVita guided to 2026 adjusted EPS of $14.10 to $15.20, adjusted operating income of $2.15 to $2.25 billion, and free cash flow of $1.0 to $1.25 billion.
What is DaVita Inc.'s market capitalization on the New York Stock Exchange?
DaVita (NYSE: DVA) had a market capitalization of about $12.4 billion in mid-September 2026, and Berkshire Hathaway owned about 45% of the shares.
Does Warren Buffett own DaVita?
Yes, Warren Buffett's Berkshire Hathaway is the massive majority shareholder of DaVita, owning roughly 40% of the entire company, attracted by the incredibly stable, recession-proof nature of chronic kidney disease treatment.
Cite or embed this data
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "DaVita Revenue & Financials." CorpDigest, https://corpdigest.com/company/davita/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>DaVita reported $13.6B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/davita/financials" target="_blank" rel="noopener">CorpDigest — DaVita financials</a></div>Related Financial Audits
Compare revenue, net income, and market cap scale
Explore DaVita
Core profile pages, founders and related research hubs for this company.